The role of MRI in prostate cancer active surveillance.

Current role of multiparametric magnetic resonance imaging in the management of prostate cancer. Korean J Urol (2015) 0.86

MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer. Int J Mol Sci (2016) 0.86

Current role of multiparametric magnetic resonance imaging for prostate cancer. Quant Imaging Med Surg (2015) 0.80

Combined PET/MRI: from Status Quo to Status Go. Summary Report of the Fifth International Workshop on PET/MR Imaging; February 15-19, 2016; Tübingen, Germany. Mol Imaging Biol (2016) 0.76

Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol (2009) 10.43

ESUR prostate MR guidelines 2012. Eur Radiol (2012) 8.86

Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol (2011) 4.99

Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol (2008) 4.90

Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol (2013) 4.64

Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24

Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol (2013) 3.34

Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol (2012) 3.30

Active surveillance for prostate cancer: progress and promise. J Clin Oncol (2011) 2.93

Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol (2006) 2.86

Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology (2005) 2.71

Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol (2010) 2.65

Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol (1997) 2.50

A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol (2000) 2.46

Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol (2003) 2.45

Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. Eur Urol (2013) 2.43

Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance? Radiology (2013) 2.35

The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29

MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. Radiology (2004) 2.16

Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol (2013) 2.16

Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology (2009) 2.16

Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol (2002) 2.11

Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis--correlation with biopsy and histopathology. J Magn Reson Imaging (2006) 1.94

Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR Am J Roentgenol (2007) 1.92

In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil. Eur Urol (2011) 1.68

Role of multiparametric 3.0-Tesla magnetic resonance imaging in patients with prostate cancer eligible for active surveillance. BJU Int (2013) 1.64

Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int (2012) 1.62

Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. BJU Int (2010) 1.52

Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study. J Urol (2012) 1.47

Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol (2010) 1.47

Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer. BJU Int (2012) 1.42

Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer (1990) 1.40

Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology (2007) 1.39

Diffusion-weighted MRI in the detection of prostate cancer: meta-analysis. AJR Am J Roentgenol (2012) 1.28

Imaging-guided prostate biopsy: conventional and emerging techniques. Radiographics (2012) 1.23

Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology (2010) 1.18

Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev (2009) 1.14

Detection and localization of prostate cancer with the targeted biopsy strategy based on ADC map: a prospective large-scale cohort study. J Magn Reson Imaging (2012) 1.10

Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. Eur Radiol (2008) 1.02

The emerging role of diffusion-weighted MRI in prostate cancer management. Nat Rev Urol (2012) 0.99

Evaluation of diffusion-weighted MR imaging at inclusion in an active surveillance protocol for low-risk prostate cancer. Invest Radiol (2013) 0.97

Mucinous adenocarcinoma of the prostate: MRI and MR spectroscopy features. AJR Am J Roentgenol (2009) 0.96

Diffusion-weighted MRI for locally recurrent prostate cancer after external beam radiotherapy. AJR Am J Roentgenol (2012) 0.92

Active surveillance or active treatment in localized prostate cancer? Dtsch Arztebl Int (2009) 0.91

Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up. Diagn Interv Radiol (2014) 0.89

Conventional imaging and multiparametric magnetic resonance (MRI, MRS, DWI, MRP) in the diagnosis of prostate cancer. Q J Nucl Med Mol Imaging (2012) 0.87

Angiogenesis in prostate cancer: biology and therapeutic opportunities. Cancer Metastasis Rev (2001) 0.87

Guided e-MRI prostate biopsy can solve the discordance between Gleason score biopsy and radical prostatectomy pathology. Magn Reson Imaging (2010) 0.85

Comparison of 8, 10, 12, 16, 20 cores prostate biopsies in the determination of prostate cancer and the importance of prostate volume. Can Urol Assoc J (2014) 0.80